An observational study purporting to show the widely-used joint pain supplement glucosamine may reduce cardiovascular disease has been met with scepticism by Australian experts. Published in the BMJ, the analysis of data from 466,039 people without cardiovascular disease found a 15% lower risk of cardiovascular events during seven years of follow up among those who ...
Glucosamine cardiovascular ‘benefit’ doesn’t stand up to scrutiny
By Michael Woodhead
16 May 2019